Default: Cytotherapy

ISSN: 1465-3249

Journal Home

Journal Guideline

Cytotherapy Q1 Unclaimed

Elsevier Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cytotherapy is a journal indexed in SJR in Cell Biology and Immunology with an H index of 91. It has a price of 2970 €. It has an SJR impact factor of 1,004 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,004.

Cytotherapy focuses its scope in these topics and keywords: cell, cells, stem, human, mesenchymal, stromal, therapy, diseasecharacterization, injuriesmulticenter, infectious, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Metrics

Cytotherapy

1,004

SJR Impact factor

91

H Index

119

Total Docs (Last Year)

332

Total Docs (3 years)

6022

Total Refs

1648

Total Cites (3 years)

309

Citable Docs (3 years)

4.82

Cites/Doc (2 years)

50.61

Ref/Doc

Comments

No comments ... Be the first to comment!

Aims and Scope


cell, cells, stem, human, mesenchymal, stromal, therapy, diseasecharacterization, injuriesmulticenter, infectious, ilil, horizonautomated, highrisk, fever, engraftment, efficacy, downstream, distinguishes, adipogenic, differentiation, differences, developments, culturesaddressing, compared, communication, cellular, adenovirusspecific, cancer, bone, autologous, application, amnionderived,



Best articles by citations

Mesenchymal stem-cell therapy in a regulated environment

View more

Cell density-dependent proliferation in frequently-fed peripheral blood mononuclear cell cultures

View more

Flow cytometric analysis of intracellular cytokines: a powerful new tool for the clinical assessment of immune responsiveness

View more

Recent advances in hematopoietic stem cell transplantation

View more

Selection and expansion of T cells from untreated patients with CLL: source of cells for immune reconstitution?

View more

Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients

View more

Minimal residual cancer

View more

FDA-NCI Workshop on Tumor Vaccines

View more

FDA's new regulatory paradigms for in vitro diagnostic devices

View more

Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study

View more

Flow cytometry in the evaluation of immune status in cancer and HIV infection

View more

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer

View more
SHOW MORE ARTICLES

Accurate calculation of blood volume to be processed by apheresis to achieve target CD34+ cell numbers for PBPC transplantation

View more

Process validation

View more

Long term cryostorage of UC blood units: ability of the integral segment to confirm both identity and hematopoietic potential

View more

Transplanted BM and BM side population cells contribute progeny to the lung and liver in irradiated mice

View more

DC-based immunotherapy of B-cell malignancies

View more

Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation

View more

A great adventure in cell therapy

View more

Evaluation in vitro of the therapeutic effect of mesenchymal stem cell-conditioned medium on drug induced liver injury

View more

Minimal tumor contamination of hematopoietic harvests from breast cancer patients can be easily detected by liquid culture assay

View more

Clinical-scale production of granulocyte progenitor and post-progenitor cells using daniplestim, leridistim, Progenipoietin, Promegapoietin and autologous plasma

View more

Adoptive T-cell therapy for CMV

View more

Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection

View more

FAQS